This article has an addendum. Addendum in: Oncotarget. 2023; 14:810-810.

Crosstalk between triple negative breast cancer and microenvironment

Karly Smrekar, Artem Belyakov and Kideok Jin _

PDF  |  Full Text  |  How to cite  |  Press Release

Oncotarget. 2023; 14:284-293. https://doi.org/10.18632/oncotarget.28397

Metrics: PDF 606 views  |   Full Text 2584 views  |   ?  


Karly Smrekar1, Artem Belyakov1 and Kideok Jin1

1 Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Science, Albany, NY 12208, USA

Correspondence to:

Kideok Jin, email: [email protected]

Keywords: triple negative breast cancer; tumor microenvironment; current therapy

Received: January 13, 2023     Accepted: March 21, 2023     Published: March 31, 2023

Copyright: © 2023 Smrekar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Although many advances have been made in the treatment of breast cancer, for the triple negative breast cancer (TNBC) these therapies have not significantly increased overall survival. Tumor microenvironment (TME) plays an essential role to develop and control TNBC progression. Many preclinical and clinical studies are ongoing to treat patients with TNBC disease, but the effective therapies are currently not available. Here, we have reviewed recent progress in understanding of TNBC and advance in defining mechanisms of TNBC therapies and potential therapeutic strategies to overcome TNBC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28397